Weekly wrap: Amgen, Pernod Ricard, Temenos

Deal flow cooled sharply in July as macroeconomic uncertainty and a sluggish private equity exit environment continued to weigh on transactions, though year-to-date activity remains ahead of 2025.

First-half deal volume and value rose from a year ago as private equity exits gained urgency, valuation expectations aligned and activity broadened across most sectors.